论文部分内容阅读
目的:探讨核苷酸切除修复交叉互补基因1(ERCC1)在晚期非小细胞肺癌中的表达及其临床意义。方法:采用免疫组化S-P法检测78例Ⅲ期、Ⅳ期非小细胞肺癌患者中核苷酸切除修复交叉互补基因1(ERCC1)的表达情况。所有患者均以铂类为基础的化疗方案化疗。将患者化疗疗效和生存资料与ERCC1的表达进行比较。结果:78例患者ERCC1的阳性表达率为47.44%(37/78),ERCC1表达与患者性别、年龄、病理类型(鳞癌、腺癌)及临床分期无关;ERCC1阴性组化疗临床受益率是73.17%(30/41),ERCC1阳性组为51.35%(19/37),两组比较差异有统计学意义(χ~2=3.9643,P=0.0465)。ERCC1阳性组生存期为(21.1852±22.1134)月,ERCC1阴性组生存期为(12.375±10.0827)月,两组比较差异无统计学意义(P=0.0879)。结论:ERCC1的表达与晚期非小细胞肺癌患者铂类药物化疗临床受益相关,检测ERCC1的表达对化疗药物的选择有一定指导意义。
Objective: To investigate the expression and clinical significance of nucleotide excision repair cross-complementary gene 1 (ERCC1) in advanced non-small cell lung cancer. Methods: The expression of nucleotide excision repair cross-complementary gene 1 (ERCC1) in 78 stage Ⅲ and Ⅳ non-small cell lung cancer patients was detected by immunohistochemical S-P method. All patients received platinum-based chemotherapy regimens. The efficacy and survival of patients with chemotherapy and ERCC1 expression data were compared. Results: The positive expression rate of ERCC1 in 78 patients was 47.44% (37/78). The expression of ERCC1 was not associated with gender, age, pathological type (squamous cell carcinoma, adenocarcinoma) and clinical stage. The clinical benefit rate of ERCC1 negative chemotherapy was 73.17 % (30/41), and ERCC1 positive group was 51.35% (19/37). There was significant difference between the two groups (χ ~ 2 = 3.9643, P = 0.0465). The survival of ERCC1 positive group was (21.1852 ± 22.1134) months, while that of ERCC1 negative group was (12.375 ± 10.0827) months. There was no significant difference between the two groups (P = 0.0879). Conclusion: The expression of ERCC1 is correlated with the clinical benefit of platinum chemotherapy in patients with advanced non-small cell lung cancer. Detecting the expression of ERCC1 may be of guiding significance for the choice of chemotherapeutics.